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Graphical Abstract 
 
An efficient synthesis of an 18F-labelled phosphonium salt containing closo-carborane is 
described. The preparation of this salt was attempted using both single-step and two-step 
protocols, with greater success found for the latter. An X-ray structure for the unlabelled 19F 
salt is also presented. 
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Lipophilic phosphonium agents (e.g. 1 and 2, Fig. 1) are known to accumulate selectively in 
the mitochondria of cancerous cells.1-3 This is attributed to the elevated mitochondrial 
membrane potential present in a broad range of cancer cells compared to healthy epithelial 
cells (ca. 60 mV e.g. −163 mV in colon carcinoma cells vs. −104 mV in kidney epithelial 
cells).2,4 Very high tumour to normal tissue uptake ratios (ca. 40 : 1) have been obtained in 
vivo for 1 and 2.1,2 The lipophilic nature of these agents, particularly the reported closo-
carborane containing salts (e.g. 3, Fig. 1),3,5,6 may facilitate their diffusion across the 
lipophilic mitochondrial membrane. Boron-containing phosphonium salts may also be useful 
in boron neutron capture therapy (BNCT), delivering boron selectively to tumour foci prior to 
neutron irradiation.7,8 
 
Figure 1: Lipophilic phosphonium agents tetraphenylphosphonium (TPP, 1), 
triphenylmethylphosphonium (TPMP, 2) and closo-carborane containing analogue 3. 
Radiolabelled phosphonium agents incorporating 18F, 11C and 64Cu for positron emission 
tomography (PET) imaging of cancer have been reported (Fig. 2).2,9-14 In vivo and in vitro 
biological distribution studies of phosphonium salts incorporating chelated 64Cu (e.g. 4) have 
shown good tumour localization and effective imaging of U87MG human glioma xenografts 
in athymic nude mice.9-11 The persistent and highly selective in vivo uptake of the 
phosphonium cation [11C]-2 has also been demonstrated. A very high tumour to healthy brain 
tissue ratio (47.5 : 1) was observed, which is one order of magnitude more selective than 
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clinically used [18F]-fluorodeoxyglucose ([18F]-FDG) or [11C]-methionine.1,15 The long-lived 
tritium agent [3H]-1 has shown selective accumulation in C6 glioma in mice in vivo 
(metastatic to normal tissue ratio 8.03 : 1) which was also more selective that clinically used 
[18F]-FDG (1.03:1).2  
 
Figure 2: Selected examples of radiolabelled phosphonium agents used in PET imaging. 
Single-12 and multi-step14 preparations of phosphonium cations incorporating 18F from the 
18F− ion have been reported (e.g. 5 and 6). The phosphonium cation [18F]-6 has proved to be 
quite versatile as an imaging agent. The selective uptake of [18F]-6 in H345 lung carcinoma in 
vivo was confirmed.13 This agent has also been used for in vivo myocardium imaging in 
healthy dogs16 and rats,17 for the assessment of severity of coronary artery stenosis in dogs in 
vivo and ex vivo,18 to quantify the time dependent apoptotic action of the chemotherapeutic 
agents paclitaxel and docetaxel in vitro and in vivo,19 and most recently to detect unstimulated 
brown adipose tissue and quantify mitochondrial thermogenic activity in rats in vivo.20 The 
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incorporation of closo-carborane, a known lipophilic pharmacophore,21 into phosphonium 
cations may facilitate their passage across the mitochondrial membrane, resulting in more 
selective cell-uptake and improved PET resolution. Biodistribution studies (e.g. microPET) 
would also be useful in assessing such salts for potential application in BNCT.22 
Radiolabelled compounds containing carboranes have been reported previously, with most 
radiolabelled carboranes comprising of radio-halogenated anionic nido-carboranes23 (e.g. 7) 
or nido-carboranes facially bound to radioactive metals such as 99mTc(I) and 57Co(III) (e.g. 8 
and 9, respectively).24,25 An 18F-labelled closo-carborane was recently described in which the 
boron cage itself was radiolabelled,26 although such entities would show compromised 
receptor binding characteristics if the closo-carborane cage is critical to receptor binding, for 
example, at hydrophobic sites. 
We have previously reported the detailed synthesis of the phosphonium salt 10.Br (Fig. 3).27 
Incorporation of the glycol moiety in 10.Br was shown to increase water solubility in 
comparison to 3.I, a methyl-containing analogue, by more than one order of magnitude (10.8 
mM vs. 0.9 mM). The covalently-bound bromine atom in 10.Br may be exchanged for a 
nucleophilic 18F− ion, and the in vivo distribution of the resulting radioproduct may be 
detected by means of PET. Herein, we report the first efficient synthesis of an 18F-
phosphonium salt containing closo-carborane ([18F]-11.I, Fig. 3) whereby the radiolabel is not 
incorporated into the carborane cage. 
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Figure 3: Previously reported glycol-containing phosphonium-carborane agent 10.Br and the 
18F-labelled analogue [18F]-11.I. 
Synthesis 
The glycol chains 12 and 13 were prepared by nucleophilic substitution of 
ditosyltetraethylene glycol with the fluoride and iodide ions, respectively (Scheme 1). The 
compounds were isolated from a statistical mixture of components. The preparation of 11.I 
from 13 was achieved according to a reported method for 10.Br27 (Scheme 1) using either 
DMF or MeCN as the solvent, and the compound was purified by trituration of the crude 
residue with Et2O and collection of the precipitate by filtration. Alternatively, small amounts 
of analytically pure 11.I were also obtained by preparative HPLC using adapted elution 
protocols.28,29 The I− counter-ion was readily replaced by CF3COO− in the HPLC mobile 
phase, yielding the final product as the 11.CF3COO salt after purification. The iodide  salt was 
then recovered by treatment of 11.CF3COO with a conc. NaI solution, followed by extraction 
of the salt into CH2Cl2. 
 
Scheme 1: Syntheses of ‘cold’ standard compounds and the precursor glycol chain for the 
radiofluorination protocol shown in Scheme 3. 
The phosphonium product 11.I exhibited similar NMR characteristics to 10.Br27 with a few 
key differences. In addition to coupling to 31P, there was also coupling by the 19F in the 1H 
and 13C NMR spectra. For example, in the 1H NMR spectrum there were two doublets of 
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triplets that were assigned to the CH2CH2F group, (δ 4.55, 2JFH = 47.9 Hz and δ 3.68, 3JFH = 
25.2 Hz) and the splitting was consistent with reported 19F−1H coupling constants.30,31 In the 
13C{1H} NMR spectrum, there were two doublets assigned to the same group, (δ 83.2, 1JFC = 
169 Hz and δ 70.4, 2JFC = 19 Hz) with splitting consistent with reported 19F−13C coupling 
constants.30,31 The 19F{1H} NMR spectrum displayed a singlet at δ −223 which was consistent 
with the 19F chemical shifts for alkyl fluorides.32,33 The 1H NMR spectra of analytically pure 
samples of 11.CF3COO obtained by HPLC before treatment with NaI were slightly different 
to the 1H NMR spectra of samples after treatment. In particular, the chemical shifts of the 
PCH2CH2 component were shifted slightly upfield (Δδ ca. 0.3) whereas all other signals in 
the 1H NMR spectrum as well as in the 11B, 19F, 13C and 31P NMR spectra were not 
significantly changed. This shift can be directly attributed to the change in counter-ion from I− 
to CF3COO−, which in CDCl3 would be closely associated with the phosphonium centre due 
to ion pairing. The presence of CF3COO− was confirmed by a sharp resonance at δ −72 in the 
19F{1H} NMR spectrum, which agrees with the literature data for the CF3 environment.32 
Furthermore, quartet resonances in the 13C{1H} NMR spectrum (δ 161.9, 2JFC = 34 Hz and δ 
117.8, 1JFC = 293 Hz) were also in agreement with literature data for the CF3COO− anion.34 
Crystals suitable for X-ray diffraction were grown by slow diffusion of Et2O into a solution of 
11.I in CDCl3, and an ORTEP representation of the salt is presented in Fig. 4.  
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Figure 4: An ORTEP depiction and atomic numbering of 11.2I.NH2Me2 with 50% 
displacement ellipsoids. 
Interestingly, the solid-state structure was found to contain two iodide counter-ions, although 
the phosphonium group itself is mono-cationic. The remaining anionic charge is balanced by 
the presence of one equivalent of adventitious NH2Me2+ ion that had co-crystallised with 11.I. 
There are clear intermolecular contacts between the N-atom and both iodide ions in the crystal 
lattice (Fig. S1). These crystals were grown from a batch of 11.I that had been prepared in 
DMF at high temperature (>100°C), and NH2Me2+ is a known decomposition product of this 
solvent which has been observed in other X-ray structures.35 Consequently, further syntheses 
of 11.I were carried out using MeCN as the solvent in place of DMF. Despite repeated 
attempts, crystallization of pure 11.I prepared in this manner did not afford X-ray quality 
crystals. 
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Radiochemistry 
The preparation of [18F]-11.Br from 10.Br in a single step was attempted as shown in Scheme 
2. The radiofluorination of a related phosphonium salt by using this method has been 
achieved previously.12 The fractions corresponding to each radiopeak in the semi-preparative 
HPLC γ-trace were collected manually and assessed by analytical HPLC. One fraction 
appeared to contain the target [18F]-11.Br product, and when this material was co-injected 
with the 11.I standard, the product and the 11.I standard eluted at exactly the same time, as 
indicated by the identical retention times of the radio- and UV-peaks (tR = 1.6 min, Fig. S2). 
This result was consistent with the target product [18F]-11.Br being successfully prepared. 
However, despite this favourable result, the retention time was too early to definitively 
confirm the identity of the product. The resulting material also possessed very low 
radioactivity, indicating a very low radiochemical yield (< 1%). Furthermore, the 
radiolabelling of 10.Br could not be reproduced in a suitably reliable manner using this single-
step method. 
 
Scheme 2: Attempted one-step synthesis of [18F]-11.Br. 
A second route toward [18F]-11.I is presented in Scheme 3. This radiosynthesis involved a 
two-step protocol whereby the [18F]-13 precursor was first prepared in good (10%) 
radiochemical yield from 12 and purified from all Kryptofix and K2CO3 residues by means of 
HPLC (Fig. S3).  The single radiopeak (tR = 4.8 min) was symmetrical and indicated the 
presence of only one product. The UV- and γ-traces confirmed it was both chemically and 
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radiochemically pure. The product was then co-injected with ‘cold’ 13. The co-incident 
retention times in the UV- and γ-traces confirm the identity of the product (Fig. S4). 
 
Scheme 3: Efficient two-step synthesis of [18F]-11.I. 
The target phosphonium salt [18F]-11.I was first prepared in DMF but the reaction proceeded 
very slowly and it was found to be increasingly susceptible to side-reactions at temperatures 
greater than 100 °C.  MeCN was then chosen as an alternative solvent. The crude product was 
purified by semi-preparative HPLC and 50 MBq of product was isolated. A sample of this 
isolated product was then tested for purity by analytical HPLC. The single radiopeak 
observed (tR = 4.3 min, Fig. S5) was symmetrical and is consistent with a single 18F-product. 
The [18F]-11.I was then co-injected with ‘cold’ 11.I; co-incident retention times in the UV- 
and γ-traces confirmed the identity of the tracer (Fig. S6). The target [18F]-11.I agent was 
obtained in ca. 3% radiochemical yield over two steps in excellent chemical and 
radiochemical purity (>99%), as confirmed by the UV- and γ-traces. 
Conclusion 
The successful synthesis of an 18F-phosphonium agent containing closo-carborane [18F]-11.I 
was achieved. We are now in a position to assess the biodistribution of these agents in animal 
models using PET imaging, and the results of this in vivo study will be reported in due course. 
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